Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05632913 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title expanded, about 1 wordv7
  2. Primary completion date: Feb 2025 to Feb 2027v6
  3. 2 versions Re-verified since Jan 17, 2024, no change to tracked fieldsv4-v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2023 to Jul 1, 2023
    v3
  5. Start date: Feb 2023 to Sep 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .
Trial Details
NCT Number NCT05632913
Lead Sponsor Alpha Tau Medical LTD.
Conditions
(from sponsor)		 Recurrent Lung Cancer, Lung Cancer
Related terms Lung Neoplasms
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov